{"database": "lobbying", "table": "lobbying_activities", "rows": [[796104, "45b0dc17-9bda-4fad-a06a-2036b6e82f28", "Q2", "AMYLIN PHARMACEUTICALS", 308536, "AMYLIN PHARMACEUTICALS", 2009, "second_quarter", "PHA", "Payment disclsoure regulations in the  Physician Payments Sunshine Act of 2009\nData exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act\nData eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726)\nRegulatory provisions in the Food and Drug Administration Globalization Act of 2009 (H.R. 759) Drug Importation/Drug Safety", "Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 320000, 0, 0, "2009-07-17T10:50:00-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["796104"], "units": {}, "query_ms": 14.993235003203154, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}